Survival data of 87 adenocarcinomas of the pancreas

Abstract

4248 Background: Pancreatic adenocarcinoma carries one of the worst prognoses among all cancers. This study aimed to determine the exact disease free and overall survival data of patients with a pancreatic adenocarcinoma, who underwent an intentive curative resection in our institution between 1992 and 2003. Methods: A retrospective analysis of survival data of consecutive cases of adenocarcinoma of the pancreas was performed. Patients of whom medical files and survival data could be traced until November 2004 or until date of death were included. Disease free survival (DFS) was defined as the time period between date of surgery until clinical, biochemical, radiological and/or pathological evidence of tumor activity. Overall survival (OS) was calculated from surgery until death or survival in November 2004. Differences in mean DFS and OS were analysed using ANOVA of the logarithmic transformation of the variable. Results: Eighty-seven patients were included: 58 men and 29 women. Mean age at diagnosis was 60.8 years (range 32–80). Eighteen patients were alive at the time of writing. Four patients died within 2 months postoperative due to cardiopulmonary complications and are excluded from the analysis. The pathological classification according to UICC (6th edition) was 9 T1, 16 T2, 49 T3, 3 T4 and 6 TX. Twenty-eight were N0, 43 N1 and 12 NX. Mean DFS for T1 was 25.7 months (95% CI 3.8–47.7), for T2 21.8 months (95% CI 8.0–35.5), for T3 16.9 months (95% CI 11.6–22.1) and for T4 5.0 months (range 2–8). These differences were not significant. Mean OS for T1 was 31.1 months (95%CI 11.1–51.1), for T2 33.0 months (95%CI 16.7–49.2), for T3 19.3 months (95%CI 15.3–23.3) and for T4 9.6 months (range 3–17). There were no significant differences found. Mean DFS for N0 [23.2 months (95%CI14.2–32.3)] was significant different from N1 [11.3 months (95%CI 6.5–16.2)](F=6.18, P<0.05). Also a significant difference was found between mean OS for NO [28.6 months (95%CI 20.6–36.7)] and for N1 [20.0 months (95%CI 13.8–26.3)](F=4.36, P<0.05). Conclusion: No difference was found in DFS and OS according to T-status. A significant better DFS and OS was found in node-negative pancreatic adenocarcinomas. No significant financial relationships to disclose.